Melatonin and Sleep Regulation

On this page

Melatonin: The Basics - Pineal's Pacemaker

  • Melatonin: A key neurohormone, often dubbed the 'hormone of darkness' due to its nocturnal secretion pattern.
  • Primary Source: Synthesized and secreted mainly by the pineal gland; also found in retina, gut.
  • Regulation: Production significantly increases (↑) in darkness and decreases (↓) with light exposure.
    • Light detected by retinal ganglion cells inhibits release via the retinohypothalamic tract to the SCN.
  • Function: Acts as a potent chronobiotic, crucial for entraining the circadian rhythm (the body's ~24-hour sleep-wake cycle).
  • Master Control: The suprachiasmatic nucleus (SCN) in the hypothalamus is the principal circadian pacemaker, orchestrating melatonin release.

    ⭐ Melatonin secretion is primarily controlled by the SCN, the master circadian pacemaker, located in the hypothalamus.

Melatonin: Synthesis & Cycle - Night's Elixir

  • Synthesis Pathway: Begins with Tryptophan.
    • Tryptophan $\rightarrow$ 5-Hydroxytryptophan $\rightarrow$ Serotonin $\rightarrow$ N-Acetylserotonin (NAS) $\rightarrow$ Melatonin.
    • 📌 Mnemonic for key steps: Try Some New Apples (Tryptophan, Serotonin, N-Acetylserotonin, Melatonin).
  • Key Enzymes in Synthesis:
    • AANAT (Arylalkylamine N-acetyltransferase): Converts Serotonin to NAS. Rate-limiting.
    • HIOMT/ASMT (Hydroxyindole-O-methyltransferase): Converts NAS to Melatonin.
Loading diagram…
  • Regulation by Light-Dark Cycle:
    • Light (via Retinohypothalamic Tract, RHT to Suprachiasmatic Nucleus, SCN) $\rightarrow$ $\downarrow$ Melatonin.
    • Darkness $\rightarrow$ SCN disinhibition $\rightarrow$ Superior Cervical Ganglion (SCG) releases Norepinephrine $\rightarrow$ $\uparrow$ Melatonin from pineal gland.

⭐ Arylalkylamine N-acetyltransferase (AANAT) is the rate-limiting enzyme in melatonin synthesis, and its activity is dramatically $\uparrow$ during darkness and suppressed by light.

Melatonin: Receptors & MOA - Switch to Slumber

  • Acts via G-protein coupled receptors (GPCRs):
    • MT1 Receptors (SCN):
      • ↓ SCN neuronal activity → promotes sleep.
      • ↓ Body temperature.
      • 📌 MT1 = Sleepy Time 1.
    • MT2 Receptors (SCN, retina):
      • Phase-shifts circadian rhythms (advancing/delaying).
      • Influences sleep timing.
      • 📌 MT2 = Time Zone 2.
    • MT3 Receptors: Enzyme quinone reductase 2; role in sleep less clear.
  • MOA:
    • Binding MT1/MT2 in SCN → inhibits adenylyl cyclase → ↓ cAMP → ↓ neuronal firing.
    • Effects: ↑ sleep propensity, circadian rhythm synchronization.

⭐ MT1 activation primarily mediates sleep promotion by inhibiting SCN neuronal activity; MT2 activation is crucial for phase-shifting circadian rhythms.

Melatonin: Clinical Uses - Timing is Everything

  • Jet Lag: Effective when taken close to target bedtime at destination. Dose: 0.5-5 mg.
  • Shift Work Sleep Disorder (SWSD): May improve daytime sleep length and quality.
  • Delayed Sleep-Wake Phase Disorder (DSWPD): Advances sleep onset; low dose hours before desired bedtime.
  • Non-24-Hour Sleep-Wake Disorder: Primarily in blind individuals; helps entrain to a 24-hour cycle.
  • Insomnia: Particularly for sleep-onset difficulties.
    • Melatonin Agonists:
      • Ramelteon: Selective MT1/MT2 agonist. Dose: 8 mg.

        ⭐ Ramelteon, a selective MT1/MT2 agonist, is approved for insomnia characterized by difficulty with sleep onset and, unlike benzodiazepines, lacks significant abuse potential or withdrawal effects.

      • Tasimelteon: For non-24-hour sleep-wake disorder.
      • Agomelatine: Antidepressant with MT1/MT2 agonistic properties.
  • Other Potential Uses:
    • Antioxidant properties.
    • Immune modulation.

High‑Yield Points - ⚡ Biggest Takeaways

  • Melatonin from pineal gland regulates circadian rhythm & sleep onset.
  • Synthesized from tryptophan via serotonin; release stimulated by darkness, inhibited by light.
  • Suprachiasmatic Nucleus (SCN) is the master circadian pacemaker, controlling melatonin secretion.
  • Melatonin levels peak mid-night, facilitating sleep maintenance and body temperature drop.
  • Acts via G-protein coupled MT1 and MT2 receptors, primarily in the SCN.
  • Clinically used for jet lag, insomnia, delayed sleep-wake phase disorder, and shift work disorder.

Unlock the full lesson and continue reading

Signup to continue reading this lesson and unlimited access questions, flashcards, AI notes, and more

Scan to download app

Scan to download
UNLOCK FREE ACCESS

Practice Questions: Melatonin and Sleep Regulation

  1. 1. Which of the following anti-Parkinson drugs can cause the adverse effect shown?

    • A. Tolcapone
    • B. Amantadine
    • C. Selegiline
    • D. Ropinirole
    Show answer

    Answer: B. Amantadine

    Amantadine - Amantadine can cause livedo reticularis, a net-like, mottled purplish discoloration caused by altered cutaneous vascular flow. - This distinctive dermatological adverse effect may occur during long-term therapy and is generally reversible after discontinuation. Tolcapone - Tolcapone is a COMT inhibitor associated with severe hepatotoxicity, requiring liver-function monitoring, rather than the described mottled skin discoloration. - Its other characteristic effects include dyskinesia, nausea, and orange urine; these findings distinguish it from amantadine-associated livedo reticularis. Selegiline - Selegiline is a selective MAO-B inhibitor whose adverse effects include insomnia and orthostatic hypotension, not the described skin mottling. - It can contribute to serotonin syndrome with certain antidepressants, but it is not associated with amantadine’s characteristic livedo reticularis. Ropinirole - Ropinirole is a dopamine agonist commonly associated with nausea and orthostatic hypotension, rather than the described vascular skin change. - It may cause impulse-control disorders, such as gambling, but does not characteristically produce livedo reticularis.

  2. 2. Which anticancer drug class is classically associated with therapy-related AML after a latency of 5–7 years, often preceded by myelodysplasia?

    • A. Antimetabolites
    • B. Vinca alkaloids
    • C. Alkylators
    • D. Taxanes
    Show answer

    Answer: C. Alkylators

    Alkylators - Alkylating agents, including cyclophosphamide, chlorambucil, melphalan, and busulfan, form covalent bonds with DNA, causing mutations and chromosomal aberrations that promote leukemogenesis. - They are strongly associated with secondary AML and MDS, typically after a 5–7-year latency, with risk increasing with cumulative dose. Taxanes - Taxanes stabilise microtubules and are not the class characteristically associated with the delayed, often MDS-preceded therapy-related AML pattern described here. Vinca alkaloids - Vinca alkaloids, including vincristine and vinblastine, inhibit microtubule formation and cell division rather than producing the DNA damage classically linked to secondary leukemia. - Their characteristic toxicities include neurotoxicity and bone marrow suppression; they are not a major cause of therapy-related AML or MDS. Antimetabolites - Antimetabolites, such as methotrexate and 5-fluorouracil, disrupt nucleotide synthesis, DNA replication, and repair, but are less strongly associated with secondary leukemias than alkylating agents. - They may cause bone marrow suppression, yet they do not characteristically produce the chromosomal damage associated with therapy-related AML and MDS.

  3. 3. Which of the following receptors mediate the release of ACTH by Vasopressin?

    • A. Oxytocin receptor
    • B. V3
    • C. V1a
    • D. V2
    Show answer

    Answer: B. V3

    V3 - V3 receptors, also called V1b receptors, are located on anterior pituitary corticotrophs and mediate vasopressin-stimulated ACTH release. - They are Gq-coupled, activating phospholipase C, increasing intracellular calcium, and promoting ACTH secretion; vasopressin acts synergistically with CRH. Oxytocin receptor - Oxytocin receptor mediates uterine contraction and milk ejection, not vasopressin-stimulated ACTH release from corticotrophs. V1a - V1a receptors primarily occur on vascular smooth muscle, where they mediate vasoconstriction, and in the liver, where they promote glycogenolysis. - Although V1a is a genuine vasopressin receptor, it does not primarily mediate ACTH release from anterior pituitary corticotrophs; that function belongs to V3/V1b. V2 - V2 receptors are located mainly on principal cells of the renal collecting ducts and mediate vasopressin’s antidiuretic effect. - Through the Gs-cAMP pathway, V2 receptors promote aquaporin-2 insertion and water reabsorption; they do not mediate pituitary ACTH release.

  4. 4. Which of the following statements is true regarding Clozapine?

    • A. Risk of agranulocytosis
    • B. Ineffectiveness in resistant schizophrenia
    • C. Routine parenteral administration
    • D. First-generation antipsychotic
    Show answer

    Answer: A. Risk of agranulocytosis

    Risk of agranulocytosis - Clozapine can cause life-threatening agranulocytosis, a severe reduction in neutrophils that increases susceptibility to infection. - Because of this risk, regular absolute neutrophil count monitoring is required, with more frequent testing during the initial treatment period. First-generation antipsychotic - Clozapine is an atypical (second-generation) antipsychotic, not a traditional or first-generation antipsychotic. - Its relatively greater D4 and 5-HT2A receptor affinity compared with D2 receptors contributes to fewer extrapyramidal effects than many traditional agents. Routine parenteral administration - Clozapine is administered orally in standard clinical practice, rather than by a parenteral route. - There is no routinely used injectable formulation of clozapine, so parenteral administration does not describe its usual clinical use. Ineffectiveness in resistant schizophrenia - Clozapine is particularly useful in treatment-resistant schizophrenia after inadequate response to at least two antipsychotic trials. - It is considered the drug of choice in resistant illness and also has evidence for reducing suicide risk in patients with schizophrenia.

  5. 5. All of the following may be used in the management of nocturnal enuresis in children EXCEPT:

    • A. Bed-wetting punishment
    • B. Imipramine therapy
    • C. Enuresis alarm therapy
    • D. Wetting calendar use
    Show answer

    Answer: A. Bed-wetting punishment

    Bed-wetting punishment is the exception because enuresis is involuntary and punishment can increase distress; management should be supportive. Evening fluids should be moderated, and voiding before sleep is recommended. Wetting calendar use helps document patterns and monitor behavioural management. Imipramine therapy is a selected, generally third-line pharmacological option because of its toxicity risks. Enuresis alarm therapy is an established conditioning treatment with durable benefit in appropriately selected children.

  6. 6. Diurnal variation of ACTH depends on ?

    • A. Supraoptic nucleus
    • B. Suprachiasmatic nucleus
    • C. Arcuate nucleus
    • D. Ventromedial hypothalamic nucleus
    Show answer

    Answer: B. Suprachiasmatic nucleus

    Suprachiasmatic nucleus is the master circadian pacemaker and coordinates the daily rhythm of ACTH secretion. Supraoptic nucleus principally contains magnocellular neurons producing vasopressin and oxytocin, rather than setting circadian timing. Arcuate nucleus contains important neuroendocrine populations, including growth hormone-releasing hormone and tuberoinfundibular dopamine neurons, but is not the master clock. Ventromedial hypothalamic nucleus participates in satiety and energy balance rather than serving as the circadian pacemaker.

  7. 7. Predominant hypothalamic regulation is stimulatory for secretion of all the following anterior-pituitary hormones EXCEPT:

    • A. ACTH
    • B. FSH
    • C. PRL
    • D. TSH
    Show answer

    Answer: C. PRL

    PRL - Prolactin is primarily inhibited by hypothalamic dopamine, also called prolactin-inhibiting hormone, rather than stimulated by a hypothalamic releasing hormone. - This is the exception because hypothalamic dopaminergic inhibition restrains prolactin release, whereas the other listed pituitary hormones are stimulated by releasing hormones. ACTH - CRH from the hypothalamus stimulates anterior-pituitary corticotrophs to synthesize and release ACTH. - ACTH does not fit the exception because hypothalamic CRH increases its secretion, after which ACTH acts on the adrenal glands. TSH - Hypothalamic TRH stimulates anterior-pituitary thyrotrophs to release TSH. - TSH does not fit the exception because TRH increases its secretion; TRH may also have a minor stimulatory effect on prolactin. FSH - Pulsatile hypothalamic GnRH stimulates anterior-pituitary gonadotrophs to produce and release FSH, along with LH. - FSH does not fit the exception because pulsatile GnRH increases gonadotropin secretion, distinguishing it from prolactin’s hypothalamic dopamine-mediated inhibition.

  8. 8. The human body has rhythmic fluctuations in its function on a circadian cycle. Circadian rhythm is controlled by:

    • A. Median eminence
    • B. Suprachiasmatic nuclei
    • C. Paramedian nuclei
    • D. Supraoptic nuclei
    Show answer

    Answer: B. Suprachiasmatic nuclei

    Suprachiasmatic nuclei - The suprachiasmatic nuclei (SCN) in the hypothalamus function as the primary master clock regulating most circadian rhythms. - The SCN receives direct retinal light input, synchronizing internal timing with the external light–dark cycle and identifying it as the correct choice. Supraoptic nuclei - The supraoptic nuclei primarily synthesize vasopressin (ADH) and oxytocin for release through the posterior pituitary, rather than acting as the circadian pacemaker. - Although located in the hypothalamus, the supraoptic nuclei regulate fluid balance and related endocrine functions, not the generation of circadian rhythms. Median eminence - The median eminence is a neurohemal organ where hypothalamic releasing and inhibiting hormones enter the portal circulation to regulate the anterior pituitary. - It may participate in endocrine responses influenced by circadian timing, but it is not the central pacemaker controlling the body’s circadian rhythm. Paramedian nuclei - Paramedian nuclei may refer to small nuclei near the midline in different brain regions, where they support various motor and sensory functions. - They are not the hypothalamic central pacemaker responsible for generating and regulating circadian rhythms.

  9. 9. Which factor best predicts response to light therapy in SAD?

    • A. Melatonin profile
    • B. Depression severity
    • C. Sleep pattern
    • D. Chronotype/Morningness-eveningness preference
    Show answer

    Answer: A. Melatonin profile

    Melatonin profile - Light therapy in SAD works primarily by resetting the circadian rhythm, which is closely tied to the melatonin secretion pattern. - An earlier timing of the dim-light melatonin onset (DLMO) in the evening (phase advance) or a delayed DLMO (phase delay) can be corrected by appropriately timed light exposure, thus predicting treatment response. Depression severity - While depression severity is a measure of the illness itself, it does not directly predict how well a patient will respond to a specific treatment modality like light therapy. - The underlying biological mechanisms responsive to light therapy are not solely determined by the degree of depressive symptoms. Sleep pattern - Sleep patterns are often disturbed in SAD, but they are a symptom of the circadian dysregulation, rather than a direct predictor of response to light therapy. - Improvements in sleep are a consequence of effective light therapy, not a prognostic factor. Chronotype/Morningness-eveningness preference - Chronotype indicates an individual's natural propensity to be a "morning person" or "evening person," reflecting their intrinsic circadian rhythm. - While related to circadian timing, it's a broader classification and less precise than the actual melatonin profile in predicting the specific timing needed for light therapy to correct phase abnormalities.

  10. 10. During polysomnography, which stage of sleep is represented by the marked areas when observing the following wave patterns? EOG (Electrooculography) EEG (Electroencephalography) EMG (Electromyography)

    • A. REM sleep
    • B. NREM I sleep
    • C. NREM II sleep
    • D. NREM III sleep
    Show answer

    Answer: B. NREM I sleep

    NREM I sleep - NREM I represents the transition from wakefulness to sleep and is marked by slow eye movements with reduced EEG frequency and theta waves. - EMG activity decreases but is not completely absent, distinguishing NREM I from the profound muscle atonia of REM sleep. NREM II sleep - NREM II is identified by EEG sleep spindles and K-complexes, which are absent from the marked area. - NREM II usually has minimal eye movements and reduced muscle activity, whereas the marked pattern indicates the transition into sleep characteristic of NREM I. NREM III sleep - NREM III requires prominent high-amplitude delta waves occupying 20–50% of the epoch, which are not present in the marked tracing. - This deepest NREM stage generally shows absent eye movements and very low muscle tone, unlike the marked pattern with slow eye movements. REM sleep - REM sleep produces rapid eye movements, a low-amplitude mixed-frequency EEG, and profound muscle atonia. - The marked tracing instead shows slow eye movements, theta activity, and reduced but persisting muscle tone, so complete REM atonia is not demonstrated.

Flashcards: Melatonin and Sleep Regulation

  1. 1. The _____ nucleus of the hypothalamus is responsible for our _____, which regulates the sleep cycle

    Show answer

    suprachiasmatic · circadian rhythm

  2. 2. Circadian rhythm: The suprachiasmatic nucleus (SCN) controls the release of _____, which stimulates the _____ gland to secrete _____

    Show answer

    norepinephrine · pineal · melatonin

  3. 3. Sleep is divided into two stages, _____ and _____

    Show answer

    REM · non-REM

  4. 4. Which nucleus of the hypothalamus is responsible for the diurnal variation of ACTH levels?

    Show answer

    Suprachiasmatic

  5. 5. Cortisol levels are highest just before _____ and lowest in the _____

    Show answer

    awakening · evening

  6. 6. Glucocorticoid (cortisol) secretion is _____ and _____ (daily) in nature, oscillating with a circadian rhythm

    Show answer

    pulsatile · diurnal

  7. 7. Pontogeniculo-occipital spikes are characteristic of sleep

    Show answer

    REM (Stage)

Everything you need for Indian Medical PG prep

Get full Oncourse access with lessons, practice questions, flashcards and AI study tools.

GET STARTED FOR FREE
75% OFFLimited time offer
GET 75% OFF